Andy Page, the president of 23andMe, is leaving his position, Recode reports. It adds that he is to remain on the firm's board of directors.
Page joined 23andMe's board in 2012, when he was president of Gilt Group, and he became 23andMe's president, which was a new position, the following year. As president, Page oversaw the firm's product and engineering, marketing, finance, business development, laboratory operations, and legal and regulatory affairs, as GenomeWeb reported at the time. This enabled 23andMe CEO and co-founder Anne Wojcicki to concentrate on the firm's research and management activities.
Recode notes that shortly after Page's arrival, 23andMe had regulatory issues to grapple with, as the US Food and Drug Administration sent the firm a warning letter in November 2013. The company had to halt its sales of its health testing kit, and it has begun to sell its kit again in a different form.
Now Recode reports that, in a letter to employees, Wojcicki wrote that "Andy and I recognize 23andMe is at a stage of strength and maturity where it would benefit from one single leader. Moving forward, Andy's direct reports will report to me."